Fig 2: The frequency of the investigated T cell subpopulations is based on the presence or absence of TIGIT and CD226 receptors in women with EO preeclampsia and healthy pregnant women. The frequency of CD3+ T- (A), CD4+ T- (B), CD8+ T- (C), and NKT (D) cell subpopulations is based on the surface presence or absence of the TIGIT and CD226 receptors in women with EO preeclampsia and healthy pregnant women. The solid bars represent medians of 24 and 27 determinations, respectively, the boxes indicate the interquartile ranges, and the lines show the most extreme observations. Differences were considered statistically significant for p-values < 0.05 **, p < 0.01 ***.

Fig 3: Frequency of TIGIT-/CD226+ and TIGIT-/CD226- cell subpopulations throughout pregnancy and in non-pregnant women. The frequency of TIGIT-/CD226- CD3+ T cells (A), TIGIT-/CD226+ NKT cells (B), TIGIT-/CD226+ CD4+ T (C) and TIGIT-/CD226- CD4+ T cells (D) in the peripheral blood during healthy pregnancy and in non-pregnant women. The solid bars represent medians, the boxes indicate the interquartile ranges, and the lines show the most extreme observations. Differences were considered statistically significant for p-values <0.03 ** and <0.05 *.

Fig 4: Granzyme B expression by the CD8+ T cell subpopulations in women with EO preeclampsia and healthy pregnant women. The intracellular expression of granzyme B molecule by CD8+ T cells in the peripheral blood of women with EO preeclampsia and healthy pregnant women (A). Granzyme B expression by CD8+ T cell subpopulations is based on the surface presence or absence of the TIGIT and CD226 receptors in women with EO preeclampsia and healthy pregnant women (B). The solid bars represent medians of 21 and 22 determinations, respectively, the boxes indicate the interquartile ranges, and the lines show the most extreme observations. Differences were considered statistically significant for p-values < 0.05 **. Representative FACS plots show the intracellular expression of granzyme B by CD8+ T cells (C). To determine the positivity of granzyme B, FMO control was used (D).

Fig 5: TIGIT expression by CD8+ cytotoxic T cells in women with EO preeclampsia and healthy pregnant women. The expression of TIGIT by CD8+ cytotoxic T cells in the peripheral blood of women with EO preeclampsia and healthy pregnant women (A). The solid bars represent medians of 24 and 27 determinations, respectively, the boxes indicate the interquartile ranges, and the lines show the most extreme observations. Differences were considered statistically significant for p-values < 0.05 **. Representative FACS plots show the expression of TIGIT surface marker by CD8+ T cells (B). To determine the positivity of the TIGIT receptor, fluorescent minus one (FMO) control was used (C).